Ann: MSB Reports Q3 Financial Results and Operational Highlights, page-217

took a position this week, ave $1.05, before this announcement coming out though.

investors who contribute in this forum have different levels of understanding over pharmaceutical sector, naturally, and i would logically assume ones further away from this industry would pay attention to words of those who's closer to it, and appreciate the value and will of such contributions, however it appears often is not the case.

the FDA site inspection itself is not worth much attention, unless this's a new facility (especially when purposely built by MSB).
such inspections, and to such existing sites more commonly the regular FDA site audits (TGA in downunder we're more familiar with), are nothing but just normal daily business. upon inspection/audits such manufacturers may often receive some observations and recommendations for CAPA corrective actions and preventive actions, but there should not be a "failure", otherwise they won't be in this business.
similarly, discussions of labelling as well, nothing but normal daily business.

the only critical thing is the clinical trial data itself, while all the others could be discussed/negotiated/improved over time.
for a better world, best wishes to MSB and GLTA contributors here.